DNA Repair and Genetic Susceptibility to Lung Cancer
This study is ongoing, but not recruiting participants.
Sponsor:
Memorial Sloan-Kettering Cancer Center
Collaborator:
University of New Mexico
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00611598
First received: January 28, 2008
Last updated: November 29, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to help us better understand the cellular changes that may lead to the development of lung cancer. We want to compare people with a second primary lung cancer with those who have only a first primary lung cancer. We hope to use the information obtained in this study as the basis for future studies and will not regard the results from this study as final.
We will analyze your blood cells and DNA to measure the changes in several genes that we believe may be involved in lung cancer. We also want to evaluate the capacity for your DNA to repair itself.
| Condition | Intervention |
|---|---|
|
Lung Cancer Single Primary Lung Cancer Second Primary Lung Cancer |
Other: Blood draw and Questionnaires |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | DNA Repair and Genetic Susceptibility to Lung Cancer |
Resource links provided by NLM:
Further study details as provided by Memorial Sloan-Kettering Cancer Center:
Primary Outcome Measures:
- To conduct a pilot study of the role of DNA repair in lung cancer subjects with high genetic risk - those with a second primary lung cancer - compared to subjects with only one lung cancer. [ Time Frame: conclusion of the study ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To determine the association between cellular DNA repair and genetic alterations in DNA repair and associated pathways. [ Time Frame: conclusion of the study ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
- 30 ml. Blood in heparinized, green top tubes.
- Fresh tumor or normal tissue, when available.
- Tissue or cells from routine bronchoscopy, when available.
| Enrollment: | 218 |
| Study Start Date: | February 2003 |
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
second primary lung cancer
|
Other: Blood draw and Questionnaires
Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
|
|
2
single primary lung cancer
|
Other: Blood draw and Questionnaires
Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
|
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
MSKCC Clinic
Criteria
Inclusion Criteria:
- Cases will be eligible for inclusion if:
- They have been diagnosed with a second primary lung cancer, and
- They speak English or a language for which we have a translated consent form, and
- They understand and agree to sign informed consent, and
- They agree to give us a blood sample, and
- They agree to give us a tissue sample when part of normal clinical procedures, and
- They agree to complete the study questionnaires, and
- They agree to have their pathology information reviewed. This could include biopsy specimens.
Controls will be eligible for inclusion if
- They have been diagnosed with a first primary lung cancer, and
- They speak English or a language for which we have a translated consent form, and
- They understand and agree to sign informed consent, and
- They agree to give us a blood sample, and
- They agree to give us a tissue sample when part of normal clinical procedures, and
- They agree to complete the study questionnaires,
- They agree to have their pathology information reviewed. This will could include biopsy specimens.
Exclusion Criteria:
- Subjects who do not meet the inclusion criteria as either cases or controls will not be eligible for this study.
- Control subjects who have a history of another cancer, other than nonmelanoma skin cancer or a first primary lung cancer, will not be eligible for this study.
- Control subjects who otherwise meet the eligibility requirements above but who have had chemotherapy and/or are currently being treated with chemotherapy will be excluded from the functional assay, but not from the genotyping.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00611598
Locations
| United States, New York | |
| Memorial Sloan Kettering Cancer Center | |
| New York, New York, United States, 10065 | |
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
University of New Mexico
Investigators
| Principal Investigator: | Irene Orlow, PhD | Memorial Sloan-Kettering Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00611598 History of Changes |
| Other Study ID Numbers: | 03-003 |
| Study First Received: | January 28, 2008 |
| Last Updated: | November 29, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Disease Susceptibility Genetic Predisposition to Disease Lung Neoplasms Disease Attributes Pathologic Processes Respiratory Tract Neoplasms |
Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 22, 2013